PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 473/34, A61K 31/52	A1	**(11) International Publication Number:** WO 99/31102 **(43) International Publication Date:** 24 June 1999 (24.06.99)

(21) International Application Number: PCT/US98/26293

(22) International Filing Date: 11 December 1998 (11.12.98)

(30) Priority Data:
60/069,371 12 December 1997 (12.12.97) US

(71) Applicant *(for all designated States except US)*: EURO-CELTIQUE, S.A. [LU/LU]; 122, boulevard de la Petrusse, L-2330 Luxembourg (LU).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CAVALLA, David [GB/GB]; 5 Tenison Avenue, Cambridge CB1 2DX (GB). CHASIN, Mark [US/US]; 3 Wayne Court, Manalapan, NJ 07726 (US). HOFER, Peter [CH/CH]; Birmannstrasse 9, CH-4410 Liestal (CH). GEHRIG, Andre [CH/CH]; Metzerstrasse 7, CH-4056 Basel (CH). WINTERGERST, Peter [CH/CH]; Gasstrasse 66, CH-4056 Basel (CH).

(74) Agents: DAVIDSON, Clifford, M. et al.; Davidson, Davidson & Kappel, LLC, 15th floor, 1140 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY



(I)

(57) Abstract

Disclosed are compounds of formula (I), wherein R^3 is selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkylalkyl or C_{3-10} cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy substituent is optionally substituted in one position with hydroxy; R^8 is selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkylalkyl or C_{3-10} cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; or benzyl, wherein said benzyl is optionally substituted in one or two positions with halogen, alkoxy, cycloalkoxy or polycycloalkyl, and wherein said alkyl moiety of said alkoxy or cycloalkoxy is optionally substituted in one position with hydroxy; R^{6a} and R^{6b} are independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkenyl, C_{3-10} cycloalkyl, C_{4-10} cycloalkylalkyl, or C_{3-10} cycloalkenyl, wherein said alkyl, alkenyl, cycloalkyl, cycloalkylalkyl or cycloalkenyl is optionally substituted in one position with hydroxy; and pharmaceutically acceptable salts thereof.